Moderna’s cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled

What happened: Moderna's stock fell after a reported leak of data for its experimental cancer vaccine developed with Merck. The Phase 3 data was expected to be shared this weekend at a medical conference. Why it matters: The stock decline followed the reported leak ahead of the scheduled conference presentation of the Phase 3 data. Key numbers: Phase 3 data Coverage: 3 outlets in 24h

Moderna's stock fell after a reported leak of data for its experimental cancer vaccine developed with Merck. The Phase 3 data was expected to be shared this weekend at a medical conference.

The stock decline followed the reported leak ahead of the scheduled conference presentation of the Phase 3 data. Key numbers: Phase 3 data